December 20, 2016
Shionogi said on December 19 that it has forged a strategic business alliance with Purdue Pharma L.P., a privately held US drug company, for the commercialization of naldemedine, a novel peripherally-acting mu-opioid receptor antagonist, in the US. Naldemedine, which will...read more